BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed

Benzinga Newsdesk www.benzinga.com Neutral 92.8%

Neg 0% Neu 92.8% Pos 0%

https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm

Comments

No comments yet. Be the first!